Features of Local Treatment of Onychomycosis
Authors/Creators
Description
Recently, the incidence of onychomycosis has been increasing. This is facilitated by poor nutrition, poor personal hygiene, decreased immunity, and changes in the body’s immune reactivity. Systemic therapy carries a risk of adverse and toxic effects. Local therapy has several advantages, the main one being minimal side effects. The antifungal agent is applied directly to the affected nail plates and is rapidly absorbed. The concentration of the antifungal agent in the lesion is sufficient to suppress the activity of pathogenic fungi. The use of topical drugs during and after systemic therapy can reduce its duration and prevent recurrence. Topical treatment begins with mechanical removal of the affected part of the nail plate and the use of keratolytic agents (urea, salicylic acid). Local antifungal drugs include azole derivatives. They disrupt ergosterol biosynthesis by inhibiting the conversion of lanosterol to ergosterol through inactivation of the enzyme 14α-demethylase, resulting in a fungistatic effect. Allylamines inhibit squalene epoxidation and its conversion to lanosterol by inactivating the enzyme squalene epoxidase. This leads to ergosterol deficiency in the cell membrane and accumulation of the toxic substance squalene in fungal cells, causing their death. Antifungal nail lacquers include terbinafine, amorolfine and ciclopirox. Amorolfine inhibits two fungal enzymes – delta-14-reductase and delta-7-8-isomerase – involved in ergosterol biosynthesis. This results in the accumulation of toxic metabolites such as squalene and desmethylsterol, leading to fungal cell death. Ciclopirox accumulates in fungal cells at high concentrations, damages the fungal cell wall, disrupts the functions of mitochondria and ribosomes, and blocks the transport of potassium ions, phosphates, and amino acids, ultimately leading to fungal death. Despite the long duration of treatment, local therapy for onychomycosis remains a safe and affordable method for combating fungal nail infection. Timely initiation of treatment and regular procedures significantly increase the chances of complete recovery of the nail plate and prevention of reinfection.
Files
haleevaFIN.pdf
Additional details
References
- 1. Borba OSM, Ogawa MM, Kirsztajn GM, Tomimori J. Onychomycosis in immunocompromised population: Phenotypic and molecular identification. Mycoses. 2023 Nov;66(11):1018-1024. DOI: 10.1111/myc.13634.
- 2. Ogawa T, Matsuda A, Ogawa Y, Tanaka R. Risk factors for the development of tinea pedis and onychomycosis: Real-world evidence from a single-podiatry center, large-scale database in Japan. J Dermatol. 2024 Jan;51(1):30-39. DOI: 10.1111/1346-8138.16991
- 3. Shofler D, Hamedani E, Seun J, Navarrete R, Thamby R, Harkless L. Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients. Clin Podiatr Med Surg. 2020 Apr;37(2):401-407. DOI: 10.1016/j.cpm.2019.12.015.
- 4. Nenoff P, Reinel D, Mayser P, et al. S1 Guideline onychomycosis. J Dtsch Dermatol Ges. 2023 Jun;21(6):678-692. DOI: 10.1111/ddg.14988
- 5. Nowicka D, Nawrot U. Tinea pedis-An embarrassing problem for health and beauty-A narrative review. Mycoses. 2021 Oct;64(10):1140-1150. DOI: 10.1111/myc.13340.
- 6. Shah AA, Mirza R, Sattar A, Khan Y, Khan SA. Unveiling onychomycosis: Pathogenesis, diagnosis, and innovative treatment strategies. Microb Pathog. 2025 Jan;198:107-111. DOI: 10.1016/j.micpath.2024.107111.
- 7. Hasegawa N, Shibuya K. Development of an Animal Model of Onychomycosis in Guinea Pigs. Med Mycol J. 2020;61(4):55-60. DOI: 10.3314/mmj.20-00011.
- 8. Leung AKC, Lam JM, Leong KF, et al. Onychomycosis: An Updated Review. Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):32-45. DOI: 10.2174/1872213X13666191026090713.
- 9. Miller RC, Lipner SR. Distinct patient characteristics and pathogenesis of fingernail only vs. fingernail and toenail onychomycosis in a retrospective single-centre academic study. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):е116-e118. DOI: 10.1111/jdv.18552.
- 10. Lee DK, Lipner SR. Optimal diagnosis and management of common nail disorders. Ann Med. 2022 Dec;54(1):694-712. DOI: 10.1080/07853890.2022.2044511.
- 11. Stewart CR, Algu L, Kamran R, et al. Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review. J Am Acad Dermatol. 2021 Nov;85(5):1227-1239. DOI: 10.1016/j.jaad.2020.05.143.
- 12. Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Tinea pedis: an updated review. Drugs Context. 2023 Jun 29;12:2023-5-1. DOI: 10.7573/dic.2023-5-1.
- 13. Schaller M, Walker B, Nabhani S, Odon A, Riel S, Jäckel A. Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis-Results of an in vitro investigation. Mycoses. 2024 Mar;67(3):e13710. DOI: 10.1111/myc.13710.
- 14. Nenoff P, Cleffmann U, Klonowski E, Uhrlaß S. Onychomykose bei Kindern und Jugendlichen – Kasuistik und Übersicht über die Literatur [Onychomycosis in children and adolescents-case report and overview of the literature]. Dermatologie (Heidelb). 2025 May;76(5):301-312. German. DOI: 10.1007/s00105-025-05502-3.
- 15. Piquero-Casals J, Morgado-Carrasco D, Granger C, Trullàs C, Jesús-Silva A, Krutmann J. Urea in Dermatology: A Review of its Emollient, Moisturizing, Keratolytic, Skin Barrier Enhancing and Antimicrobial Properties. Dermatol Ther (Heidelb). 2021 Dec;11(6):1905-1915. DOI: 10.1007/s13555-021-00611-y.
- 16. Annunziata MC, Cacciapuoti S, Cosentino C, Fabbrocini G. Urea-containing topical formulations. Int J Clin Pract. 2020 Dec;74 Suppl 187:e13660. DOI: 10.1111/ijcp.13660.
- 17. Jiang Y, Li W, Deng S, et al. Flumethasone-salicylic acid cream effectively flattened verrucous epidermal nevus: a case report. J Dermatolog Treat. 2026 Dec;37(1):2603129. DOI:: 10.1080/09546634.2025.2603129.
- 18. Kappes S, Faber T, Nelleßen L, Yesilkaya T, Bock U, Lamprecht A. Improving Transungual Permeation Study Design by Increased Bovine Hoof Membrane Thickness and Subsequent Infection. Pharmaceutics. 2021 Dec 6;13(12):2098. DOI: 10.3390/pharmaceutics13122098.
- 19. Yazdanpanah S, Jabrodini A, Motamedi M, et al. Species distribution and antifungal susceptibility profiles of yeasts isolated from onychomycosis: a cross-sectional study with insights into emerging species. Antonie Van Leeuwenhoek. 2023 Dec 28;117(1):6. DOI: 10.1007/s10482-023-01914-0.
- 20. Shemer A, Eshel Y, Gupta AK, et al. Once Weekly Application of Urea 40% and Bifonazole 1% Leads to Earlier Nail Removal in Onychomycosis. Skin Appendage Disord. 2020 Sep;6(5):304-308. DOI: 10.1159/000508926.
- 21. Wang H, Wang Y, Liu J, et al. Experimental research on fungal inhibition using dissolving microneedles of terbinafine hydrochloride nanoemulsion for beta-1,3-glucanase. Nanoscale Adv. 2025 Jun 6;7(15):4636-4650. DOI: 10.1039/d5na00163c.
- 22. Joly-Tonetti N, Legouffe R, Tomezyk A, et al. Penetration Profile of Terbinafine Compared to Amorolfine in Mycotic Human Toenails Quantified by Matrix-Assisted Laser Desorption Ionization-Fourier Transform Ion Cyclotron Resonance Imaging. Infect Dis Ther. 2024 Jun;13(6):1281-1290. DOI: 10.1007/s40121-024-00979-2.
- 23. Joly-Tonetti N, Legouffe R, Tomezyk A, et al. Penetration Profiles of Four Topical Antifungals in Mycotic Human Toenails Quantified by Matrix-Assisted Laser Desorption Ionization-Fourier Transform Ion Cyclotron Resonance Imaging. Infect Dis Ther. 2024 Jun;13(6):1269-1279. DOI: 10.1007/s40121-024-00978-3.
- 24. Trailokya AA, Shirsat AB, Madhu R, Shah B. Naftifine: A Topical Allylamine for Superficial Dermatophytosis. J Assoc Physicians India. 2023 May;71(5):11-12. DOI: 10.5005/japi-11001-0241.
- 25. Ahuja A, Bajpai M. Nanoformulations Insights: A Novel Paradigm for Antifungal Therapies and Future Perspectives. Curr Drug Deliv. 2024;21(9):1241-1272. DOI: 10.2174/0115672018270783231002115728.
- 26. Blume-Peytavi U, Tosti A, Falqués M, et al. A multicentre, randomised, parallel-group, double-blind, vehicle-controlled and open-label, active-controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis. Mycoses. 2022 Apr;65(4):392-401. DOI: 10.1111/myc.13392.
- 27. Luan J, Zhang Z, Wang Q, et al. The Role of LC3-Associated Phagocytosis Inhibits the Inflammatory Response in Aspergillus fumigatus Keratitis. Invest Ophthalmol Vis Sci. 2024 Jul 1;65(8):4. DOI: 10.1167/iovs.65.8.4.
- 28. Douge R, Belaouni M, Merhari F, Yadari ME, Er-Rami M. Atypical presentation of eczematiform dermatophytid secondary to Trichophyton rubrum onychomycosis: a case report and literature review. Pan Afr Med J. 2024 Dec 16;49:122. DOI: 10.11604/pamj.2024.49.122.45946.
- 29. Kaul G, Akhir A, Shukla M, et al. Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus In Vitro and In Vivo. Microbiol Spectr. 2023 Aug 17;11(4):e0503122. DOI: 10.1128/spectrum.05031-22.
- 30. Agafonova MN, Kazakova RR, Lubina AP, et al. Antibacterial activity profile of miramistin in in vitro and in vivo models. Microb Pathog. 2020 May;142:104072. DOI: 10.1016/j.micpath.2020.104072.
- 31. Wykowski R, Fuentefria AM, de Andrade SF. Antimicrobial activity of clioquinol and nitroxoline: a scoping review. Arch Microbiol. 2022 Jul 30;204(8):535. DOI: 10.1007/s00203-022-03122-2.